BACKGROUND

In the past 10 years, programmed death (PD)-1 and PD ligand (PD-L)1 inhibitors have become increasingly attractive for therapy of many solid tumours.1 PD-1/PD-L1 checkpoint inhibitors, such as pembrolizumab, nivolumab and atezolizumab, have been approved by the US Food and Drug Administration for 17 different types of advanced unresectable cancers, in first- and later-line treatment settings.2 These agents are key mediators of local immunosuppression in the tumour microenvironment (TME) and regulate T-cell activation and proliferation to attack tumour cells.2,3 PD-1/PD-L1 inhibitors have demonstrated clinical efficacy in terms of overall survival (OS) and progression-free survival (PFS).4,5

However, tumour resistance, especially acquired resistance, blocks further, widespread use of PD-1/PD-L1 inhibitors. Furthermore, pancreatic and prostate cancers are particularly resistant to this treatment approach.6 Therefore, combination strategies have been suggested. They may exert immunopotentiating effects by increasing the mutational load in cancer cells and increasing the sensitivity of tumour cells to T cells.7 In non–small-cell lung cancer (NSCLC), PD-1/PD-L1 inhibitors initially demonstrated efficacy as monotherapy.8 Combination of platinum-based chemotherapy...
with PD-1/PD-L1 inhibitors improved efficacy.\textsuperscript{4,9-11} The efficacy of combination of PD-1/PD-L1 inhibitors with ipilimumab is also encouraging in melanoma.\textsuperscript{12} Besides, combination of PD-1/PD-L1 inhibitors with nab-paclitaxel in breast cancer\textsuperscript{13} and with dabrafenib and trametinib in melanoma\textsuperscript{14} has shown similar efficacy. There are now >100 ongoing clinical trials of PD-1/PD-L1 inhibitors as monotherapy or in combination with other agents in different tumour types.\textsuperscript{15} Nevertheless, the use of these agents can be limited by adverse events (AEs), such as nausea, fatigue, decreased appetite, diarrhoea and vomiting.\textsuperscript{16} The clinical benefit associated with combination PD-1/PD-L1 inhibitors should be balanced against associated toxicity.

Addition of PD-1/PD-L1 inhibitors to treatment remains controversial, and individual studies are not sufficient to clarify this. Whether PD-1/PD-L1 checkpoint inhibitors will achieve significant efficacy for all tumour types or different therapeutic schedules is still up for question. Therefore, we performed a meta-analysis of efficacy for all tumour types or different therapeutic schedules is now controversial, and individual studies are not sufficient to clarify this. Whether PD-1/PD-L1 checkpoint inhibitors will achieve significant efficacy for all tumour types or different therapeutic schedules is still up for question. Therefore, we performed a meta-analysis of phase II/III randomized controlled trials to compare the efficacy and safety of combination PD-1/PD-L1 checkpoint inhibitors for malignant solid tumours. It is important for clinical policymakers to explore the degree of efficacy in different tumour types, therapeutic schedules and therapy lines. Additionally, the incidence of AEs may provide clinicians with important and clinically useful information.

2 | MATERIALS AND METHODS

2.1 | Search strategy

This meta-analysis was performed with PubMed, Web of Science, Medline, EMBASE and Cochrane Library from their inception until January 2020 to identify relevant studies. A combination of free-text terms and medical subject headings terms was used for the subject search. Search terms included “nivolumab” OR “BMS 936558” OR “BMS 936559” OR “MDX 1105” OR “pembrolizumab” OR “lambrolizumab” OR “MK 3475” OR “pidilizumab” OR “CT 011” OR “durvalumab” OR “MEI 4736” OR “atezolizumab” OR “MPDL 3280a” OR “avelumab” OR “AMP 224” OR “PD-1” OR “PD-L1” OR “programmed death 1” OR “programmed death ligand 1” OR “programmed cell death ligand 1” OR “B7-H1” OR “CD274” AND “tumor” OR “cancer” OR “carcinoma” OR “neoplasm” OR “malignancy” OR “sarcoma”. We also had two researchers independently screen the titles and abstracts of the retrieved articles.

2.2 | Study selection

Studies were included if they met the following criteria. (a) Literature type: phase II/III randomized controlled trials. (b) The experimental intervention group was treated with combination PD-1/PD-L1 checkpoint inhibitors with other therapies (immunotherapy, chemotherapy, targeted therapy and radiotherapy), whereas the control group received other therapies without PD-1/PD-L1 inhibitors. (c) Efficacy and safety data were available. Exclusion criteria were as follows: (a) studies with post-operative adjuvant therapy and neoadjuvant therapy; (b) not in English; and (c) multiple articles that analysed the same trials. In the latter case, we analysed the latest data.

2.3 | Data extraction and quality assessment

Data from each study were extracted by two researchers independently. A third researcher was consulted to reach a majority decision. The following information was used: (a) authors’ names, year of publication, tumour type, therapy lines, sample size and interventions; and (b) the primary efficacy outcomes were OS and PFS, and the secondary outcome was AEs. The meta-analysis was conducted in accordance with the guidelines of the Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols (PRISMA-P) 2015 statement.\textsuperscript{17}

2.4 | Statistical analysis

We calculated the hazard ratio (HR) and 95% confidence interval (CI) for OS and PFS and the risk ratio (RR) and 95% CI for AEs. We also performed subgroup analyses of OS, PFS and incidence of grade 3-5 AEs for patients with different tumour types, therapeutic schedules and therapy lines. Revman version 5.3 (The Cochrane Collaboration) was used to perform the meta-analysis. Heterogeneity between studies was evaluated using the chi-squared test and $I^2$ statistics. Because of the complexity of the control conditions and the variety of solid tumours, a random-effect model was used to enhance the credibility of the results. We used Begg’s and Egger’s tests with Stata SE version 12 (Stata Corporation), with significance set at $P < 0.1$, to evaluate publication bias. All the statistical tests were two-sided, and $P < 0.05$ was considered statistically significant.

3 | RESULTS

3.1 | Eligible studies and characteristics

The search strategy generated 26 502 relevant clinical records from the five databases. After screening and eligibility assessment, 19 eligible\textsuperscript{5,14,18-34} phase II/III randomized controlled trials were selected for meta-analysis, including 10 178 patients. The detailed search and study selection process is shown in Figure 1. In addition, RCTs was evaluated with the Cochrane Collaboration tool, which demonstrated relatively high methodological quality (Figures S1 and S2).

3.2 | Study characteristics and quality

The basic characteristics of the selected studies are shown in Table 1. Most of the 19 studies were of chemotherapy and targeted...
therapy, including 8 chemotherapy + PD-1/PD-L1 vs chemotherapy; 6 targeted therapy + PD-1/PD-L1 vs targeted therapy; 2 immunotherapy (ipilimumab) + PD-1/PD-L1 vs immunotherapy (ipilimumab); 1 best supportive care (BSC) + PD-1/PD-L1 vs BSC; 1 chemotherapy + targeted therapy + PD-1/PD-L1 vs chemotherapy + targeted therapy; and 1 chemoradiotherapy + PD-1/PD-L1 vs chemoradiotherapy. To analyse comparability further, we also recorded the basic tumour types and the different lines of therapy. There were 7 different tumour types, namely NSCLC (n = 3), renal tumour types and the different lines of therapy. There were 7 different tumour types, namely NSCLC (n = 3), renal tumour types and the different lines of therapy. There were 7 different tumour types, namely NSCLC (n = 3), colorectal cancer (n = 1), breast cancer (n = 1) and head and neck carcinoma (n = 1). There were 14 trials with first-line therapy and 5 with second or beyond lines of therapy.

3.3 | OS

OS was reported in 18 studies. Subgroup analyses for OS are summarized in Figure 2. According to the different therapeutic schedules, tumours and therapy lines, we conducted three subgroup analyses. Combined PD-1/PD-L1 inhibitors prolonged OS [HR 0.72, 95% CI (0.65-0.79), P < 0.001]. Eighteen of the selected studies examined HR of OS based on therapeutic schedules and tumour types in total population (Figures 2 and 3). PD-1/PD-L1 inhibitors combined with chemotherapy (P < 0.0001), targeted therapy (P = 0.05), immunotherapy (ipilimumab) (P < 0.001) and chemoradiotherapy (P = 0.004) was associated with better OS compared with the control groups. Immunotherapy (ipilimumab) plus PD-1/PD-L1 had the greatest effect on OS [HR 0.57, 95% CI (0.45-0.72), P < 0.001]. OS was significantly improved in melanoma (P < 0.001), NSCLC (P < 0.001) and SCLC (P < 0.001), and melanoma and NSCLC had significantly better clinic benefit (HR 0.58, P < 0.001) and (HR 0.66, P < 0.001), respectively. Combination therapy with PD-1/PD-L1 inhibitors significantly prolonged OS after first-line treatment [HR 0.69, 95% CI (0.61-0.79), P < 0.001] and second or additional lines of treatment [HR 0.76, 95% CI (0.68-0.86), P < 0.001]. In addition, combination first-line treatment with PD-1/PD-L1 inhibitors had better clinical efficacy than second or additional lines of therapy (Figure S3).

3.4 | PFS

PFS was reported in all 19 studies. Results of subgroup analyses for PFS are summarized in Figure 4. We conducted three subgroup analyses according to different therapeutic schedules, tumours and therapy lines. Combination immunotherapy significantly prolonged PFS [HR 0.66, 95% CI 0.59-0.75, P < 0.001]. When the 19 studies were grouped by therapeutic schedules or tumour types, our meta-analysis showed that all groups achieved different degrees of benefit (Figures 4 and 5). Immunotherapy (ipilimumab) plus PD-1/PD-L1 inhibitor had the most significant effect [HR 0.41, 95% CI (0.35-0.49), P < 0.001]. Among the tumour types, melanoma showed the greatest benefit [HR 0.45, 95% CI (0.34-0.59), P < 0.001]. We demonstrated that combination therapy with PD-1/PD-L1 inhibitors had longer PFS in first-line than in second or additional lines of therapy [HR 0.59, 95% CI (0.52-0.66), P < 0.001] and [HR 0.85, 95% CI (0.73-1.00), P = 0.06] (Figure S4).

3.5 | Incidence of grade 3-5 AEs

The incidence of grade 3-5 AEs was examined in 5568 patients in the experimental groups and 4416 patients in the control groups. We performed subgroup analysis according to the different therapeutic schedules and tumour types. The incidence of grade 3-5 AEs was not significant in the 2 subgroup analyses (HR 1.10, 95% CI 0.99-1.23, P = 0.07). According to the subgroup analysis, immunotherapy (ipilimumab) plus PD-1/PD-L1 inhibitor had AEs [HR 2.22, 95% CI (1.83-2.68), P < 0.001], compared with the control group (Figure 6 and Figure S5).

3.6 | Incidence of all-grade and grade 3/4 AEs

The incidence of all-grade and grade 3/4 AEs was examined in 5315 patients in the experimental groups and 4258 patients in the control groups. A total of 9573 patients experienced AEs of any grade. Combination therapy with PD-1/PD-L1 inhibitors had no significant advantage [RR 1.01, 95% CI (0.99-1.01), P = 0.31] compared with the control group (Figure S6). Due to the large number of AEs reported, we selected the most common all-grade and grade 3/4 AEs for analysis (Table 2). The most common all-grade AEs were fatigue (RR = 0.99), nausea (RR = 0.97), diarrhoea (RR = 1.08) and decreased appetite (RR = 0.98). The incidence of most AEs was not increased by PD-1/PD-L1 inhibitors, except for a significant decrease in anaemia (all-grade RR 0.70, P = 0.003, grade 3/4 RR 0.71, P = 0.04) and significant increase in rash (all-grade RR 1.46, P < 0.0001, grade 3/4 RR 1.08, P < 0.0001).

3.7 | Publication bias

Begg’s test (P = 0.198 > 0.1) and Egger’s test (P = 0.34 > 0.1) showed no significant publication bias in OS (Figure S7).

4 | DISCUSSION

In the past 10 years, >10 cancers have been recommended for treatment with PD-1/PD-L1 checkpoint inhibitors, with objective response rates of 10%-30% and good toxicity. Compared with traditional therapies, PD-1/PD-L1 inhibitors can prolong survival because of the memory of the adaptive immune system. Nevertheless, we have to acknowledge that many patients do not benefit from the treatment or relapse after a period of response, especially in breast and colon cancers. Tumour-mediated
mechanisms of immunotherapy resistance are improved by synergism with targeted therapies or chemotherapy. Many studies have demonstrated that combination with chemotherapy, molecular-targeted therapy and immunotherapy has good curative effect and adequate safety.

In the presence of efficacy based on therapeutic schedules, we found that adding PD-1/PD-L1 inhibitors to various therapeutic schedules achieved different degrees of clinical benefit. In 8 chemotherapy groups, combined chemotherapy with PD-1/PD-L1 inhibitors achieved the impressive efficacy, which was consistent with recent clinical trials. A pre-clinical trial showed that chemotherapy induces PD-L1 overexpression via nuclear factor-κB, which aggravates immunosuppression in ovarian cancer. The mechanisms of action of chemotherapeutic agents include the death of tumour cells with immunogenicity, reduced immunosuppressive effect and sensitization of tumour cells to immune effector cells. When it comes to adding PD-1/PD-L1 inhibitors, many studies have investigated the mechanism. Firstly, combination therapies can increase cross-presentation of tumour antigens and up-regulation of major histocompatibility complex (MHC) class I antigens. Secondly, in the presence of interleukin (IL)-2, IL-5 and other cytokines, combination therapies enhance CD8 T-cell activation and their ability to attack tumour cells.

Our research indicated that the addition of PD-1/PD-L1 inhibitors prolonged OS and PFS notably in molecular-targeted treatment. There has been an increase in the use of anti-vascular endothelial growth factor (VEGF) agents for molecular-targeted therapy. VEGF, IL-10 and prostaglandin E2 are released by cells and exert systemic immunosuppressive effects in the TME. Consequently, these cytokines and growth factors may
### TABLE 1  Study characteristics

| Author, year | Phase | Tumour | Line | Sample size | Interventions |
|--------------|-------|--------|------|-------------|---------------|
| **Experimental** | **Control** |
| Antonia 2018 | III | NSCLC | 1L | 476 237 | Chemoradiotherapy + Durvalumab | Chemoradiotherapy + Placebo |
| Ascierto 2019 | II | Melanoma | 1L | 60 60 | Dabrafenib + Trametinib + Pembrolizumab | Dabrafenib + Trametinib + Placebo |
| Borghaei 2019 | IIIB/IV | NSCLC | 1L | 60 63 | Pemetrexed-carboplatin + Pembrolizumab | Pemetrexed-carboplatin |
| Eng 2019 | III | Colorectal cancer | 2L | 183 90 | Cobimetinib + Atezolizumab | Regorafenib |
| Ferris 2016 | III | Carcinoma of the Head and Neck | 2L | 240 121 | Chemotherapy + Nivolumab | Chemotherapy |
| Finn 2020 | III | HCC | 2L | 278 135 | BSC + Pembrolizumab | BSC + Placebo |
| Gandhi 2018 | II | NSCLC | 1L | 410 206 | Pemetrexed + Platinum-based drug + Pembrolizumab | Pemetrexed + Platinum-based drug + Placebo |
| Hodi 2016 | II | Melanoma | 1L | 95 47 | Ipilimumab + Nivolumab | Ipilimumab + Placebo |
| Hodi 2018 | III | Melanoma | 1L | 314 315 | Ipilimumab + Nivolumab | Ipilimumab |
| Horn 2018 | III | SCLC | 2L | 201 202 | Chemotherapy + Atezolizumab | Chemotherapy + Placebo |
| McDermott 2018 | II | RCC | 1L | 101 101 | Bevacizumab + Atezolizumab | Sunitinib |
| Motzer 2019 | III | RCC | 1L | 442 444 | Axitinib + Avelumab | Sunitinib |
| Paz-Ares 2018 | III | NSCLC | 1L | 278 281 | Chemotherapy + Pembrolizumab | Chemotherapy + Placebo |
| Paz-Ares 2019 | III | SCLC | 2L | 268 269 | Platinum-etoposide + Durvalumab | Platinum-etoposide |
| Reck 2019 | III | NSCLC | 1L | 400 400 | Bevacizumab + Chemotherapy + Paclitaxel + Atezolizumab | Bevacizumab + Chemotherapy + Paclitaxel |
| Rini (1) 2019* | III | RCC | 1L | 454 461 | Bevacizumab + Atezolizumab | Sunitinib |
| Rini (2) 2019* | III | RCC | 1L | 432 429 | Axitinib + Pembrolizumab | Sunitinib |
| Schmid 2020 | III | Breast Cancer | 1L | 451 451 | Nab-paclitaxel + Atezolizumab | Nab-paclitaxel + Placebo |
| West 2019 | III | NSCLC | 1L | 483 240 | Chemotherapy + Atezolizumab | Chemotherapy |

Abbreviations: 1L, first line; 2L, second line or beyond; BSC, best supportive care; HCC, hepatocellular carcinoma; NSCLC, non–small-cell lung cancer; RCC, renal cell carcinoma; SCLC, small-cell lung cancer.

*Rini published two articles in the same year. We marked Rini (1) and Rini (2) in order to make a better distinction.
down-regulate anticancer immunity of cytotoxic T lymphocytes.\(^{45}\)

Anti-VEGF agents have been shown to have multiple mechanisms of action.\(^{43,46}\) Some studies\(^ {47,48}\) have reported that anti-VEGF agents up-regulate PD-L1 on endothelial cells and tumour cells and cause abnormal vascularization in mouse models, which aggravates immunosuppression. It has been suggested that treatment with PD-1/PD-L1 inhibitors ameliorates immune escape and promotes normalization of tumour vasculature.\(^ {44,49}\)

Only one included article mentioned that combined PD-1/PD-L1 inhibitors with radiotherapy improved the curative effect. When radiotherapy is combined with PD-1/PD-L1 inhibitors, it can increase inflammatory processes, restrain leucocyte adhesion to ECs, promote apoptosis and reduce oxidative burst in macrophages.\(^ {50}\) In NSCLC, radiotherapy can up-regulate tumour cell PD-L1 expression.\(^ {51}\)

Besides, the greatest benefit was observed with immunotherapy (ipilimumab) when plus PD-1/PD-L1 inhibitors for malignant
### FIGURE 3  Forest Plot of Hazard ratio of OS based on tumour types in total population

| Subgroup                      | log[Hazard Ratio] | SE  | Weight | Hazard Ratio      | Hazard Ratio            |
|-------------------------------|-------------------|-----|--------|-------------------|-------------------------|
|                               |                   |     |        | IV. Random. 95% CI| IV. Random. 95% CI       |
| **1.6.1 Melanoma**            |                   |     |        |                   |                         |
| Ascierto 2019                 | -0.2744           | 0.3149 | 2.0%   | 0.76 [0.41, 1.14] |                         |
| Hodi 2016                     | -0.3011           | 0.277 | 2.4%   | 0.74 [0.43, 1.27] |                         |
| Hodi 2018                     | -0.6162           | 0.1045| 7.4%   | 0.54 [0.44, 0.66] |                         |
| Subtotal (95% CI)             |                   |     |        |                   |                         |
| Heterogeneity: Tau² = 0.00; Chi² = 1.97, df = 2 (P = 0.37); I² = 0% | | |
| Test for overall effect: Z = 5.89 (P < 0.00001) | | |

| **1.6.2 NSCLC**                |                   |     |        |                   |                         |
| Antonia 2018                  | -0.3857           | 0.1865| 4.2%   | 0.68 [0.47, 0.98] |                         |
| Borghaei 2019                 | -0.5798           | 0.2855| 2.3%   | 0.56 [0.32, 0.98] |                         |
| Gandhi 2018                   | -0.7133           | 0.1297| 6.2%   | 0.49 [0.38, 0.63] |                         |
| Paz-Ares 2018                 | -0.4463           | 0.1363| 5.9%   | 0.64 [0.49, 0.84] |                         |
| Reck 2019                     | -0.2744           | 0.0957| 7.8%   | 0.76 [0.63, 0.92] |                         |
| West 2019                     | -0.2231           | 0.1059| 7.3%   | 0.80 [0.65, 0.98] |                         |
| Subtotal (95% CI)             |                   |     |        |                   |                         |
| Heterogeneity: Tau² = 0.02; Chi² = 10.74, df = 5 (P = 0.06); I² = 53% | | |
| Test for overall effect: Z = 4.90 (P < 0.00001) | | |

| **1.6.3 Head and Neck Carcinoma** |                   |     |        |                   |                         |
| Ferris 2016                    | -0.3567           | 0.1616| 5.0%   | 0.70 [0.51, 0.96] |                         |
| Subtotal (95% CI)              |                   |     |        |                   |                         |
| Heterogeneity: Not applicable | | |
| Test for overall effect: Z = 2.21 (P = 0.03) | | |

| **1.6.4 HCC**                  |                   |     |        |                   |                         |
| Finn 2020                      | -0.2472           | 0.1252| 6.4%   | 0.78 [0.61, 1.00] |                         |
| Subtotal (95% CI)              |                   |     |        |                   |                         |
| Heterogeneity: Not applicable | | |
| Test for overall effect: Z = 1.97 (P = 0.05) | | |

| **1.6.5 SCLC**                 |                   |     |        |                   |                         |
| Horn 2018                      | -0.3567           | 0.1324| 6.1%   | 0.70 [0.54, 0.91] |                         |
| Paz-Ares 2019                  | -0.3147           | 0.1086| 7.2%   | 0.73 [0.59, 0.90] |                         |
| Subtotal (95% CI)              |                   |     |        |                   |                         |
| Heterogeneity: Tau² = 0.00; Chi² = 0.06, df = 1 (P = 0.81); I² = 0% | | |
| Test for overall effect: Z = 3.95 (P < 0.0001) | | |

| **1.6.6 RCC**                  |                   |     |        |                   |                         |
| Motzer 2019                    | -0.2485           | 0.1746| 4.6%   | 0.78 [0.55, 1.10] |                         |
| Rini (1) 2019                  | -0.0726           | 0.103 | 7.4%   | 0.93 [0.76, 1.14] |                         |
| Rini (2) 2019                  | -0.6349           | 0.1698| 4.7%   | 0.53 [0.38, 0.74] |                         |
| Subtotal (95% CI)              |                   |     |        |                   |                         |
| Heterogeneity: Tau² = 0.07; Chi² = 8.03, df = 2 (P = 0.02); I² = 75% | | |
| Test for overall effect: Z = 1.76 (P = 0.08) | | |

| **1.6.7 Breast Cancer**        |                   |     |        |                   |                         |
| Schmid 2022                    | -0.1508           | 0.0907| 8.0%   | 0.86 [0.72, 1.03] |                         |
| Subtotal (95% CI)              |                   |     |        |                   |                         |
| Heterogeneity: Not applicable | | |
| Test for overall effect: Z = 1.66 (P = 0.10) | | |

| **1.6.8 colorectal cancer**    |                   |     |        |                   |                         |
| Eng 2019                       | 0                 | 0.1606| 5.0%   | 1.00 [0.73, 1.37] |                         |
| Subtotal (95% CI)              |                   |     |        |                   |                         |
| Heterogeneity: Not applicable | | |
| Test for overall effect: Z = 0.00 (P = 1.00) | | |

Total (95% CI) 100.0% 0.72 [0.65, 0.79]

Heterogeneity: Tau² = 0.02; Chi² = 37.42, df = 17 (P = 0.003); I² = 55%
Test for overall effect: Z = 6.83 (P < 0.00001)
Test for subgroup differences: Chi² = 15.07, df = 7 (P = 0.04), I² = 53.6%
solid tumours. Combination of PD-1 and cytotoxic T lymphocyte-associated antigen-4 has the potential to increase response rates in patients with renal cell carcinoma. Other immune checkpoints, including lymphocyte activation gene 3 and T-cell immunoglobulin 3, may also enhance antitumour T-cell immunity when PD-1/PD-L1 inhibitors are added.

In subgroup analysis based on tumour types, our meta-analysis demonstrated that OS and PFS were increased in melanoma more than in other tumours. Just as Sharma said, melanoma had substantial effect on immunological activity and potential synergy when combination strategy was designed with molecularly targeted therapy. Some studies have demonstrated that BRAF-targeted...
FIGURE 5  Forest Plot of Hazard ratio of PFS based on tumour types in total population
therapy increases expression of antigenic proteins, restores MHC-I surface expression, increases T-cell infiltration, facilitates T-cell cytotoxicity and a more favourable TME, which helps PD-1/PD-L1 checkpoint inhibitors to reduce the effect of immune resistance. The OS and PFS of first-line treatment were significantly higher than those of second-line or beyond treatment.
Our meta-analysis demonstrated that combination treatment with PD-1/PD-L1 checkpoint inhibitors did not significantly increase incidence of all-grade AEs. Nearly 95% of patients experienced at least 1 AE, which is consistent with Hoffner. Second, when immunotherapy (ipilimumab) plus PD-1/PD-L1 or combination PD-1/PD-L1 inhibitors used in melanoma, the rate of grade 3-5 AEs showed AEs increased significantly, which is also consistent with previous results. The most common AEs were fatigue, nausea and diarrhoea. The incidence of rash was raised rapidly, which might be attributed to the use of PD-1/PD-L1 inhibitors. It has been shown that PD-1 blockade increases the risk of immune-mediated AEs when combined with chemotherapy. We think that the decline of anaemia could be due to the addition of PD-1/PD-L1 inhibitors 3267 patients of included studies receiving lower dose chemotherapy in experiment group than 2470 patients in control group.

As far as we known, the present study is the first to analyse comprehensively the efficacy and safety of combination treatment with PD-1/PD-L1 checkpoint inhibitors for malignant solid tumours. Our study had several advantages. First, the data were extracted from 19 multicenter phase II/III randomized controlled trials that involved over 10,000 patients, which had high-quality designs. Second, multiple subgroups were analysed, according to the types of tumours, agents and therapies. Third, we evaluated the incidence of all-grade AEs and grade 3-5 AEs, respectively.

Our study also had some limitations. First, some of the included subgroups were too small to evaluate effectively, such as HCC, breast cancer, colorectal cancer and chemoradiotherapy. Second, the promising biomarkers of PD-L1 tumour proportion scores and tumour mutation burden were not measured in subgroup analysis because of the lack of sufficient data. Third, we did not consider drug doses, or baseline patient characteristics, such as sex and age.

The clinic benefits and risk of AEs, as well as costs, should be considered. Our findings revealed the efficacy of combination treatment with PD-1/PD-L1 checkpoint inhibitors for malignant solid tumours, and it did not result in unexpected toxicity. In the future, detection of PD-L1 expression, microsatellite analysis and combination with other therapies, such as molecular-targeted agent, chemotherapy or radiotherapy, will allow further subgroup validation in order to select the most appropriate and economic treatment.

### Table 2: Subgroup analysis of the adverse events (AEs)

| Experimental vs. control | No. of studies | RR   | 95% CI       | P   | Heterogeneity (I²) |
|--------------------------|----------------|------|--------------|-----|--------------------|
| Any grade adverse events | 19             | 1.01 | 0.99-1.02    | .31 | 68                 |
| Any grade fatigue        | 19             | 0.99 | 0.91-1.07    | .79 | 48                 |
| Any grade nausea         | 19             | 0.97 | 0.83-1.13    | .84 | 84                 |
| Any grade diarrhoea      | 19             | 1.08 | 0.90-1.29    | .42 | 87                 |
| Any grade decreased appetite | 19         | 0.98 | 0.84-1.15    | .79 | 72                 |
| Any grade vomiting       | 17             | 1.05 | 0.83-1.33    | .67 | 79                 |
| Any grade anaemia        | 15             | 0.70 | 0.56-0.88    | .003| 89                 |
| Any grade rash           | 14             | 1.46 | 1.28-1.66    | <.0001| 21                |
| Any grade constipation   | 13             | 1.08 | 0.98-1.19    | 1.3 | 0                  |
| Any grade asthenia       | 13             | 0.92 | 0.82-1.03    | .15 | 8                  |
| 3/4 grade adverse events | 19             | 1.08 | 1.04-1.12    | <.0001| 86                |
| 3/4 grade nausea         | 19             | 1.06 | 0.74-1.52    | .76 | 0                  |
| 3/4 grade fatigue        | 19             | 0.94 | 0.66-1.35    | .76 | 49                 |
| 3/4 grade decreased appetite | 19         | 1.26 | 0.76-2.08    | .37 | 27                 |
| 3/4 grade diarrhoea      | 19             | 1.25 | 0.92-1.68    | .15 | 34                 |
| 3/4 grade vomiting       | 16             | 0.91 | 0.58-1.41    | .66 | 0                  |
| 3/4 grade anaemia        | 15             | 0.71 | 0.51-0.99    | .04 | 75                 |
| 3/4 grade rash           | 15             | 1.61 | 0.95-2.73    | .08 | 0                  |
| 3/4 grade asthenia       | 13             | 0.87 | 0.61-1.25    | .46 | 4                  |
| 3/4 grade constipation   | 13             | 1.63 | 0.70-3.77    | .26 | 0                  |
5 | CONCLUSIONS

For malignant solid tumours, patients treated with first- or second-line combination therapy with PD-1/PD-L1 inhibitors had significantly prolonged PFS and OS, with only a small increase in the incidence of AEs.

CONFLICT OF INTEREST

The authors declare that they have no conflict of interest.

AUTHOR CONTRIBUTIONS

Qigu Yao: Data curation (lead); formal analysis (lead). Lihu Gu: Data curation (equal); formal analysis (equal); methodology (equal); software (equal). Rong Su: Formal analysis (equal); methodology (equal); software (equal). Bangsheng Chen: Data curation (equal); formal analysis (equal); methodology (equal); software (equal); supervision (equal). Hongcui Cao: conceptualization (lead); supervision (lead); writing-review and editing (lead).

ETHICAL APPROVAL

This article does not contain any studies with human participants or animals performed by any of the authors.

DATA AVAILABILITY STATEMENT

The data used to support the findings of this study are included within the article.

ORCID

Hongcui Cao https://orcid.org/0000-0002-6604-6867

REFERENCES

1. Callahan MK, Postow MA, Wolchok JD. Targeting T cell co-receptors for cancer therapy. *Immunity*. 2016;44(5):1069-1078.
2. Topalian SL, Taube JM, Pardoll DM. Neoadjuvant checkpoint blockade for cancer immunotherapy. *Science* (New York, NY). 2020;367(6477).
3. Dong H, Strome SE, Salomao DR, et al. Tumor-associated B7–H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. *Nat Med*. 2002;8(8):793-800.
4. Gadgeel SM, Stevenson JP, Langer CJ, et al. Pembrolizumab and platinum-based chemotherapy as first-line therapy for advanced non-small-cell lung cancer: phase 1 cohorts from the KEYNOTE-021 study. *Lung cancer* (Amsterdam, Netherlands). 2018;125:273-281.
5. Paz-Ares L, Luft A, Vicente D, et al. Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer. *N Engl J Med*. 2018;379(21):2040-2051.
6. Dallavalle S, Dobričić V, Lazzarato L, et al. Improvement of conventional anti-cancer drugs as new tools against multidrug resistant tumors. *Drug Resist Updat*. 2020;50:100682.
7. Hato SV, Khong A, de Vries II, Lesterhuis WJ. Molecular pathways: the immunogenic effects of platinum-based chemotherapeutics. *Clin Cancer Res*. 2014;20(11):2831-2837.
8. Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. *N Engl J Med*. 2015;373(17):1627-1639.
9. Langer CJ, Gadgeel SM, Borghaei H, et al. Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study. *Lancet Oncol*. 2016;17(11):1497-1508.
10. Lazzari C, Karachalious I, Bulotta A, et al. Combination of immunotherapy with chemotherapy and radiotherapy in lung cancer: is this the beginning of the end for cancer? *Ther Adv Med Oncol*. 2018;10:1758835918762094.
11. Yoneda K, Imanishi N, Ichiki Y, Tanaka F. Immune Checkpoint Inhibitors (ICIs) in Non-Small Cell Lung Cancer (NSCLC). *J UOEH*. 2018;40(2):173-189.
12. Rozeman EA, Menzies AM, van Akkooi ACJ, et al. Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial. *Lancet Oncol*. 2019;20(7):948-960.
13. Prowell TM, Beaver JA, Pazdur R. Residual disease after neoadjuvant therapy - developing drugs for high-risk early breast cancer. *N Engl J Med*. 2019;380(7):612-615.
14. Asciento PA, Ferrucci PF, Fisher R, et al. Dabrafenib, trametinib and pembrolizumab or placebo in BRAF-mutant melanoma. *Nat Med*. 2019;25(6):941-946.
15. Keung EZ, Ukponmwan EU, Cogdill AP, Wargo JA. The rationale and emerging use of neoadjuvant immune checkpoint blockade for solid malignancies. *Ann Surg Oncol*. 2018;25(7):1814-1827.
16. Hoffner B, Leigh NB, Davies M. Toxicity management with combination chemotherapy and programmed death 1/programmed death ligand 1 inhibitor therapy in advanced lung cancer. *Cancer Treat Rev*. 2020;85:101979.
17. Shamseer L, Moher D, Clarke M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. *BMJ (Clinical research ed)*. 2015;350(undefined):g7647.
18. Antonia SJ, Villegas A, Daniel D, et al. Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC. *N Engl J Med*. 2018;379(24):2342-2350.
19. Borghaei H, Langer CJ, Gadgeel S, et al. 24-Month overall survival from KEYNOTE-021 cohort G: pemetrexed and carboplatin with or without pembrolizumab as first-line therapy for advanced nonsquamous non-small cell lung cancer. *J Thorac Oncol*. 2019;14(1):124-129.
20. Eng C, Kim TW, Bendell J, et al. Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trial. *Lancet Oncol*. 2019;20(6):849-861.
21. Ferris RL, Blumenschein G, Fayette J, et al. Nivolumab for recurrent squamous-cell carcinoma of the head and neck. *N Engl J Med*. 2016;375(19):1856-1867.
22. Finn RS, Ryoo BY, Merle P, et al. Pembrolizumab as second-line therapy in patients with advanced hepatocellular carcinoma in KEYNOTE-240: a randomized, double-blind, phase III trial. *J Clin Oncol*. 2020;38(3):193-202.
23. Gandhi L, Rodríguez-Arribas D, Gadgeel S, et al. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. *N Engl J Med*. 2018;378(22):2078-2092.
24. Hodi FS, Chiarion-Sileni V, Gonzalez R, et al. Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial. *Lancet Oncol*. 2018;19(11):1480-1492.
25. Hodi FS, Chesney J, Pavlick AC, et al. Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial. *Lancet Oncol*. 2016;17(11):1558-1568.
26. Horn L, Mansfield AS, Szczęsna A, et al. First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer. *N Engl J Med*. 2018;379(23):2220-2229.
27. McDermott DF, Huseni MA, Atkins MB, et al. Clinical activity and molecular correlates of response to atezolizumab alone or in...
28. Motzer RJ, Penkov K, Haanen J, et al. Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med. 2019;380(12):1103-1115.

29. Motzer RJ, Penkov K, Haanen J, et al. Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial. Lancet (London, England). 2019;394(10212):1929-1939.

30. Reck M, Mok TSK, Nishio M, et al. Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial. Lancet Respir Med. 2019;7(5):387-401.

31. Rini BI, Powles T, Atkins MB, et al. Atezolizumab plus bevacizumab and chemotherapy as first-line treatment of advanced renal cell carcinoma. N Engl J Med. 2019;380(12):1116-1127.

32. Schmid P, Rugo HS, Adams S, et al. Atezolizumab plus nab-paclitaxel versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial. Lancet (London, England). 2019;393(10189):2404-2415.

33. Batchelor TT, Sorensen AG, di Tomaso E, et al. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vascularization and alleviates edema in glioblastoma patients. Cancer Cell. 2007;11(1):83-95.

34. Tian L, Goldstein A, Wang H, et al. Mutual regulation of tumour vessel normalization and immunostimulatory reprogramming. Nature. 2017;544(7649):250-254.